- Home
- GNSS vs TLSA Comparison
GNSS vs TLSA Comparison
Compare GNSS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- TLSA
- Stock Information
- Founded
- GNSS 1992
- TLSA 2013
- Country
- GNSS United States
- TLSA United Kingdom
- Employees
- GNSS N/A
- TLSA N/A
- Industry
- GNSS Consumer Electronics/Appliances
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- TLSA Health Care
- Exchange
- GNSS Nasdaq
- TLSA Nasdaq
- Market Cap
- GNSS 98.9M
- TLSA 175.3M
- IPO Year
- GNSS N/A
- TLSA 2000
- Fundamental
- Price
- GNSS $1.77
- TLSA $1.51
- Analyst Decision
- GNSS Strong Buy
- TLSA
- Analyst Count
- GNSS 3
- TLSA 0
- Target Price
- GNSS $5.33
- TLSA N/A
- AVG Volume (30 Days)
- GNSS 115.4K
- TLSA 261.4K
- Earning Date
- GNSS 08-05-2025
- TLSA 07-11-2025
- Dividend Yield
- GNSS N/A
- TLSA N/A
- EPS Growth
- GNSS N/A
- TLSA N/A
- EPS
- GNSS N/A
- TLSA N/A
- Revenue
- GNSS $27,780,000.00
- TLSA N/A
- Revenue This Year
- GNSS $91.14
- TLSA N/A
- Revenue Next Year
- GNSS $75.44
- TLSA N/A
- P/E Ratio
- GNSS N/A
- TLSA N/A
- Revenue Growth
- GNSS N/A
- TLSA N/A
- 52 Week Low
- GNSS $1.46
- TLSA $0.63
- 52 Week High
- GNSS $4.04
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- GNSS 61.79
- TLSA 48.99
- Support Level
- GNSS $1.48
- TLSA $1.53
- Resistance Level
- GNSS $1.85
- TLSA $1.81
- Average True Range (ATR)
- GNSS 0.09
- TLSA 0.11
- MACD
- GNSS 0.04
- TLSA -0.01
- Stochastic Oscillator
- GNSS 92.31
- TLSA 11.76
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.